Hellenic Institute for the Study of Sepsis
Hellenic Institute for the Study of Sepsis
Explore linked clinical trials.8 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL | Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome | Recruiting | Phase 3 | 2026-10-08 | NCT07813767 | |
| CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL | Community-Acquired Infections, Community-Acquired Pneumonia, Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, pneumonia, respiratory system disorder, respiratory tract infectious disorder | Recruiting | Phase 3 | 2026-10-02 | NCT07834346 | |
| Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. | COVID-19, Community-Acquired Infections, Community-Acquired Pneumonia, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, Respiration Disorders, cardiovascular disorder, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Not stated | 2026-07-06 | NCT06601998 | |
| Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial) | Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome | Active, not recruiting | Phase 3 | 2026-01-16 | NCT05909683 | |
| Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome | COVID-19, Chronic Disease, Coronaviridae Infections, Disease Attributes, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, RNA Virus Infections, long COVID-19, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Phase 2 / Phase 3 | 2026-01-08 | NCT05926505 | |
| Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) | Community-Acquired Infections, Community-Acquired Pneumonia, Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, pneumonia, respiratory system disorder, respiratory tract infectious disorder | Recruiting | Phase 3 | 2025-12-16 | NCT06294600 | |
| Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial) | Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome | Active, not recruiting | Phase 2 | 2025-11-19 | NCT06694701 | |
| The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19 | COVID-19, Coronaviridae Infections, Disease Attributes, Infections, Nidovirales infectious disease, Noncommunicable Diseases, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Not stated | 2025-11-17 | NCT06608849 |